Source - LSE Non-Regulatory
RNS Number : 6866X
PayPoint PLC
06 January 2022
 

 

PRESS RELEASE

PAYPOINT AND RANDOX PARTNER TO BOOST ACCESSIBILITY OF DAY 2 TESTING

The updated collaboration opens up PayPoint's extensive retail network to offer increased convenience to travellers returning to the UK

6 January 2022, Welwyn Garden City: PayPoint and Randox have today announced an expansion of their partnership, to boost access to COVID-19 testing and provide a vital service to travellers returning to the UK, in line with the Government's new arrival requirements for Day 2 testing, announced on Wednesday 5th January.

The expanded partnership between PayPoint and Randox will mean even easier access to low-cost COVID-19 testing, by enabling people to order a Randox test online for click and collect at a local store within the Collect+ network, initially available in over 5,000 locations, and soon in over 10,000 locations nationwide.

The service launches on 7th January 2022 to coincide with changes to travel policy which, from 4am on 9th January, allows fully vaccinated arrivals from non-red list countries to take a lateral flow (antigen) test, with a PCR test only required if a positive lateral flow result is returned.

In addition, from mid-January, PayPoint will give consumers the ability to walk into a local store and pick up a test immediately in over 2,500 locations, with no need to order online. This service will be offered in partnership with major convenience retailers including Scotmid Co-operative and Spar in the North West and Scotland.

Dr Peter FitzGerald, Managing Director at Randox said: "By drawing on our 40 years' diagnostics experience, unparalleled testing capacity, and well-established logistics network, which now includes an extensive number of new locations from PayPoint, Randox is able to respond quickly to changing travel requirements and simplify the process of ordering Day 2 lateral flow tests.

"The availability of value for money tests that can be collected at the customer's convenience thanks to our partnership with PayPoint means people in the UK don't need to wait for home delivery or a walk-in clinic appointment when ordering a COVID-19 test."

Nick Wiles, Chief Executive at PayPoint said: "Our expanded partnership with Randox will deliver yet another vital service to help keep people safe in communities across the UK.  Consumer convenience and accessibility are at the very heart of what we do and this is another example of our agility, responsiveness and the great relationships we have with our retailer partners in the ever-changing landscape across the UK."

Day 2 lateral flow tests must be ordered before travel to England and can be ordered from 4am on 7th January. Thanks to the updated collaboration between PayPoint and Randox, people can now conveniently collect these tests from local stores for just £18.95, rather than waiting at home for deliveries to arrive.

Using the free Randox CertiFly App results are processed within 3 hours and a report delivered in-app and via email, allowing arrivals into England to complete their Day 2 test conveniently in the comfort of their own home, and for individuals who test positive, potentially reducing the amount of time they need to isolate.   

-ENDS-

PayPoint Press Office                                                   
MHP Communications
paypoint@mhpc.com
+44 20 3128 8100

Randox Press Office

Ian Monk

ian@ianmonk.com 

+44 7970 026072 / + 44 203 011 1933

 

ABOUT PAYPOINT GROUP

For tens of thousands of businesses and millions of consumers, we deliver innovative technology and services that make life a little easier.

The PayPoint Group serves a diverse range of organisations, from SME and convenience retailer partners, to local authorities, multinational service providers and e-commerce brands. Our products are split across three core business divisions:

·    In Shopping, we enhance retailer propositions and customer experiences through EPoS services via PayPoint One, card payment technology, Counter Cash, ATMs and home delivery technology partnerships in over 60,000 SME and retailer partner locations across multiple sectors. Our retail network of over 28,000 convenience stores is larger than all the banks, supermarkets and Post Offices put together

·    In E-commerce, we deliver best-in-class customer journeys through Collect+, a tech-based delivery solution that allows parcels to be sent, picked up and dropped off at thousands of local stores

·    In Payments and Banking, we help companies and their customers make and receive payments quickly and conveniently. This includes our digital payments platform, MultiPay, an eMoney offering that enables cash through to digital transactions and cash solutions providing vital consumer access across our extensive retail network

Together, these solutions enable The PayPoint Group to create long-term value for all stakeholders, including customers, communities and the world we live in.

 

ABOUT RANDOX

Established in 1982, Randox is the largest healthcare diagnostics company from the UK and Ireland; undertaking research, development, manufacture and distribution of innovative laboratory tests and analysers.  In 2020 Randox manufactured 4.2 billion tests and operated in 145 countries.  With over 2,000 staff, including 450 research scientists and engineers, key facilities are located in Co Antrim, Co Donegal, London, Liverpool and Dublin.

 Randox focuses on the provision of timely and accurate testing in order to identify risk to health, improve clinical diagnoses and promote preventative healthcare; aiming to achieve better healthcare outcomes whilst reducing the burden on clinical services. The company's comprehensive portfolio includes tests for cardiovascular disease, diabetes, cancer, Alzheimer's disease and stroke.

Randox's proprietary Biochip Technology allows many tests to be run simultaneously, greatly improving the diagnostic power available to clinicians.  This innovation enables Randox Health Clinics in Liverpool, London and Northern Ireland to provide advanced health screening involving hundreds of diagnostic tests.  Such health checks provide an extraordinary insight into a person's current and future health.

 In early 2020 Randox recognised the threat from COVID-19 and, based on almost 40 years of diagnostic experience, quickly developed a test to accurately identify the virus.  Testing at scale commenced within weeks to support the UK's National Testing Programme and private clients. 

Through the enormous effort and commitment of its staff Randox is subsequently operating at a capacity of 180,000 COVID-19 samples per day, making it amongst the very largest COVID-19 laboratories in the UK and Europe. Randox has surpassed 23 million gold-standard PCR tests for the National Testing Programme and private COVID testing for travel.

Randox is clear that better diagnostics are unquestionably critical to future improvements within healthcare and is committed to remaining at the forefront of that field. 

 


 

 

                                                                               

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAZZGGMDVFGZZM
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.